Holen Sie sich die Stockscreener-App
65.35
1.41%
0.91
Handel nachbörslich:
65.96
0.61
+0.93%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$64.44
Offen:
$63.93
24-Stunden-Volumen:
8.99M
Relative Volume:
1.70
Marktkapitalisierung:
$202.63B
Einnahmen:
$51.21B
Nettoeinkommen (Verlust:
$6.50B
KGV:
33.01
EPS:
1.98
Netto-Cashflow:
$6.76B
1W Leistung:
-1.85%
1M Leistung:
+3.40%
6M Leistung:
-16.82%
1J Leistung:
-0.65%
1-Tages-Spanne:
$63.75
$65.47
1-Wochen-Bereich:
$63.75
$67.47
52-Wochen-Spanne:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
65.35 | 202.63B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
Why Astrazeneca (AZN) Outpaced the Stock Market Today - Yahoo Finance
Analysts are saying the AstraZeneca share price looks cheap despite China turmoil - MSN
AstraZeneca takes advantage of Tanium’s integrations with Microsoft & ServiceNow - Tech Monitor
Beijing Woos AstraZeneca for Investment While Probe Continues - BNN Bloomberg
AstraZeneca PLC ADR falls Thursday, underperforms market - MarketWatch
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman - GlobeNewswire
AstraZeneca outperforms market despite losses on the day - MarketWatch
AstraZeneca PLC Announcement: If You Have Suffered Losses - GlobeNewswire
AstraZeneca strengthens global operations despite China challenges - IG
AstraZeneca PLC ADR underperforms Wednesday when compared to competitors - MarketWatch
AstraZeneca falls Wednesday, underperforms market - MarketWatch
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexif - Quantisnow
AstraZeneca insiders expect sales dip in China after arrest of local boss - Financial Times
Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action InvestigationAZN - Morningstar
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
AstraZeneca is expanding in Cambridge as it plans to grow Mass. presence - The Business Journals
Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN - Business Wire
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
AstraZeneca rises Monday, outperforms market - MarketWatch
AstraZeneca's SWOT analysis: oncology giant's stock poised for growth - Investing.com
AstraZeneca announces board refresh with new directors - Investing.com
AstraZeneca PLC (NASDAQ:AZN) Short Interest Down 8.3% in November - MarketBeat
AstraZeneca goes cheap – should you buy? - MoneyWeek
AstraZeneca: two appointments to the Board of Directors - Marketscreener.com
AstraZeneca Strengthens Board with New Non-Executive Director Appointments - TipRanks
AstrazenecaPotential Approval For Soliris Would Mark First An… - Marketscreener.com
AstraZeneca names new non-executive directors - Investing.com
AstraZeneca Strengthens Leadership with New Appointments - Devdiscourse
3 Unstoppable Stocks to Buy Right Now - The Motley Fool
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by State Street Corp - MarketBeat
Peapack Gladstone Financial Corp Grows Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Verition Fund Management LLC Has $338,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response - Citeline News & Insights
AstraZeneca PLC ADR underperforms Friday when compared to competitors - MarketWatch
AstraZeneca falls Friday, underperforms market - MarketWatch
AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Franklin Resources Inc. - MarketBeat
Wilmington Savings Fund Society FSB Buys New Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Vestcor Inc Has $1.02 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Hutchmed to get Takeda milestone payment - Marketscreener.com
AstraZeneca ups job losses to 7,600 as cuts costs - Reuters
AstraZeneca Partners with Tracer Bio for Revolutionary Cancer Monitoring Technology - StockTitan
AstraZeneca’s Anna Berg Asberg on Scaling Generative AI at AI Summit New York - IoT World Today
AstraZeneca rises Thursday, outperforms market - MarketWatch
Virtu Financial LLC Purchases New Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca: Lynparza shows promise in breast cancer - Marketscreener.com
Pitavastatin Market Key Players AnalysisPfizer Inc., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc. - openPR
AstraZeneca Sees Bright Future For Registry-Based Randomized Clinical Trials - News & Insights
AstraZeneca PLC ADR rises Wednesday, still underperforms market - MarketWatch
AstraZeneca, Merck report positive long-term data for Lynparza - MSN
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients - Yahoo Finance
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):